GLP-1 Prescription Eligibility in 2026: Updated BMI and Health Criteria

Eligibility for GLP-1 prescriptions follows established medical criteria — but those criteria have evolved significantly as clinical evidence has expanded and new indications have been approved. Here’s where things stand in 2026.

The Standard BMI Criteria

FDA-approved indications for chronic weight management (Wegovy, Zepbound) require either BMI ≥30 (obesity) or BMI ≥27 with at least one weight-related comorbidity. The qualifying conditions include type 2 diabetes or prediabetes, hypertension, dyslipidemia (high cholesterol/triglycerides), obstructive sleep apnea, cardiovascular disease, and non-alcoholic fatty liver disease (MASLD).

For compounded GLP-1 prescriptions, individual providers may apply slightly different criteria. Some prescribe at BMI ≥25 with documented metabolic dysfunction. The physician’s clinical judgment determines eligibility within the bounds of standard medical practice.

Beyond BMI: The 2026 Landscape

The medical community increasingly recognizes that BMI alone is an imperfect measure of metabolic health. The AMA recommended in 2023 that BMI be used alongside other measures like waist circumference, body composition, and metabolic biomarkers. Some providers now use waist-to-hip ratio, visceral fat assessment, or the Body Roundness Index (BRI) as supplementary criteria.

Cardiovascular indication: Following the SELECT trial, semaglutide received FDA approval for cardiovascular risk reduction in patients with obesity and established heart disease. This created a separate eligibility pathway independent of the weight loss indication.

Who Does NOT Qualify

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Pregnancy or active breastfeeding — GLP-1 medications are contraindicated
• History of pancreatitis — relative contraindication requiring careful physician assessment
• Active eating disorders (anorexia nervosa, bulimia) — appetite-suppressing medications are contraindicated
• Severe gastroparesis — GLP-1 medications slow gastric emptying further
• Under 12 years old (semaglutide approved 12+ for obesity; tirzepatide adult-only as of 2026)

The Insurance vs. Self-Pay Divide

Eligibility criteria differ depending on your payment path. Insurance plans often apply stricter criteria — requiring documented BMI, failed lifestyle interventions, specific diagnoses, and sometimes step therapy (trying cheaper medications first). Self-pay through telehealth providers typically follows the FDA-approved criteria without additional administrative hurdles.